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Abstract

Introduction: Amylin receptor serves as a portal for the expression of deleterious effects of amyloid
b-protein (Ab), a key pathologic hallmark of Alzheimer’s disease. Previously, we showed that
AC253, an amylin receptor antagonist, is neuroprotective against Ab toxicity in vitro and abrogates
Ab-induced impairment of hippocampal long-term potentiation.
Methods: Amyloid precursor protein–overexpressing TgCRND8 mice received intracerebroventricularly AC253 for 5 months. New cyclized peptide cAC253 was synthesized and administered intraperitoneally three times a week for 10 weeks in the same mouse model. Cognitive functions were
monitored, and pathologic changes were quantified biochemically and immunohistochemically.
Results: AC253, when administered intracerebroventricularly, improves spatial memory and
learning, increases synaptic integrity, reduces microglial activation without discernible adverse effects in TgCRND8 mice. cAC253 demonstrates superior brain permeability, better proteolytic stability, and enhanced binding affinity to brain amylin receptors after a single intraperitoneal injection.
Furthermore, cAC253 administered intraperitoneally also demonstrates improvement in spatial memory in TgCRND8 mice.
Discussion: Amylin receptor is a therapeutic target for Alzheimer’s disease and represents a diseasemodifying therapy for this condition.
Ó 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia [1], which is characterized by deposition of amyloid
b-protein (Ab) intracellularly and extracellularly within
cortical and limbic brain structures that are critical for memory and cognitive functions [2–4]. A central question in AD
1
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research is the amyloid protein is a cause or a consequence
of the disease, and at present, it appears that the likely
answer is both [5]. Several lines of evidence strongly support
a role for Ab in the pathogenesis of AD: (1) AD is associated
with inherited amyloid precursor protein (APP) mutations,
(2) neurotoxicity of soluble oligomeric Ab when applied to
neurons, and (3) APP-overexpressing mice that recapitulate
certain neuropathologic and behavioral features of AD
[6–9]. On the other hand, adverse events in clinical trials for
AD using Ab vaccine-based therapy and the subsequent failure of monoclonal antibody therapies and inhibitors of the
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Ab-generating gamma-secretase enzyme in improving cognitive functions in patients [6] have forced a rethink of these approaches as disease-modifying treatment strategies in AD.
Nonetheless, it is hard to imagine a definitive treatment for
AD that will not serve to ameliorate in some form the neurotoxic effects of Ab, because this is a key “upstream” event in
AD pathogenesis (as established by alterations in cerebrospinal fluid (CSF) Ab levels decades before clinical onset) [7].
Multiple receptors have been implicated in mediating Ab
disruption of neuronal and synaptic processes in AD and thus
identified as potential targets for developing anti-Ab therapies,
although none have fulfilled this goal yet [8,9]. Importantly, the
amylin receptor, comprising heterodimers of the calcitonin
receptor (CTR) with receptor activity-modifying proteins
(RAMPs), serves as a portal for the expression of deleterious
effects of Ab and human amylin (hAmylin) [10]. Amylin is a
37-amino acid peptide hormone that is cosecreted with insulin
by beta cells of the pancreas that control glucose levels in
blood; however, amylin has the propensity to aggregate and
form amyloid oligomers and fibrils in the pancreas in type 2
diabetes [11] and in AD brains [12]. Our prior studies show
that hAmylin, like Ab, causes dysfunction and death of neurons
preferentially affected in AD [13,14]. Furthermore, amylin
receptor antagonists, such as AC253 (a 24-amino acid peptide),
are neuroprotective against Ab-induced toxicity [13,15]
and can reverse impairment of Ab- or hAmylin-induced
depression of hippocampal long-term potentiation (LTP), a
cellular surrogate of memory [16]. Recently, two other groups
have reported similar cognitive therapeutic benefits with pramlintide [17,18], a synthetic nonamyloidogenic analog of
amylin, and our recent findings have further confirmed
that pramlintide acts in a manner similar to AC253 by
attenuating Ab- and hAmylin-induced depression of LTP [19].
Herein, we first tested the in vivo therapeutic efficacy of
AC253 in an AD mouse model and show that chronic intracerebroventricular (icv) administration of the amylin receptor antagonist, AC253, improves learning and memory
deficits in transgenic APP-overexpressing (TgCRND8)
mice. These behavioral improvements coincided with an increase in synaptic-related proteins, including synapsin 1 and
synaptophysin, along with a decrease in the microglia
marker, Iba1. We further developed and tested a new disulfide head-to-tail cyclized version of the AC253 peptide
(cAC253). cAC253 shows enhanced brain penetration after
a single intraperitoneal (ip) injection and demonstrates
improved proteolytic stability and pharmacokinetic
behavior compared with its linear counterpart AC253.
Importantly, using a panel of genetically engineered mice
with different levels of amylin receptor expression, we
show that systemically administered cAC253 is strongly
localized to the hippocampal region, which coincides with
the distribution of amylin receptors in the brain, and its concentration in the brain correlates with the expression levels
of the amylin receptor in the brain. Finally, ip administration
of cAC253 for 10 weeks attenuates cognitive decline and improves learning and memory impairments in TgCRND8
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mice, which occurs in parallel with a reduction in cerebral
Ab deposits. Taken together, our findings identify the amylin
receptor as a viable target for disease-modifying therapies in
AD and that the amylin receptor antagonist, cAC253, is a
new promising therapeutic candidate in AD patients.
2. Methods
2.1. In vivo mouse models and in vitro cell models
All in vivo experiments were carried out in accordance
with the relevant laws and guidelines set by the Canadian
Council for Animal Care and with the approval of the Animal Care Use Committee (Health Sciences) at the University
of Alberta. For behavioral experiments, APP overexpressing
transgenic (TgCRND8) and wild-type (Wt) littermate mice
(male and female) were implanted with Alzet minipumps
(Durect Co, Cupertino, CA) through which icv artificial
CSF or AC253 (2.4 mg/day) was continuously administered
for 5 months beginning at the age of 3 months. Morris Water
Maze (MWM) and T-maze testing for spatial memory were
performed at the age of 3 and 8 months. For in vivo behavioral experiments involving peripheral (ip) administration
of cAC253, TgCRND8 and Wt mice (male and female)
were equally and randomly distributed into four groups,
Tg-NS (n 5 10; NS [normal saline]), Tg-cAC253
(n 5 10), Wt-NS (n 5 10), and Wt-cAC253 (n 5 10).
Mice received ip injections of either NS or cAC253
(200 mg/kg) three times a week starting at the age of
3.5 months for 10 weeks. All behavioral experiments were
carried out double-blinded, that is, the individual testing
behavior was blinded to drug treatments. For the MWM,
mice learn to locate a hidden platform using spatial cues
outside the maze, and all animals underwent 7 days of hidden
platform testing. After completion of training, a probe trial
was performed in which the platform was removed and putative indices of spatial memory were measured. T-maze
test is a simple reward base test for spatial memory, where
animals are required to correctly identify the food arm of
the maze and scored on latency and correct responses. Heterozygous CTR (het CTR) mice (C57BL/6J background)
with a 50% deletion of CTR [20] were obtained from Drs
R. A. Davey and J. D. Zajac (Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria).
Primary human fetal neurons (HFNs), mouse neuronal cell
line (N2a cells), HEK293 cells stable expressing amylin 3
(AMY3) subtype of amylin receptors were used for in vitro
characterized amylin receptor antagonism effects.
2.2. Immunohistochemistry, protein, and cytotoxicity
assays
Immunohistochemistry, enzyme-linked immunosorbent
assay (ELISA), and Western blot analysis were carried out
on brain sections from all treatment groups in Wt and
TgCRND8 mice to examine Ab burden, amylin receptors
(CTR and RAMP3), and synaptic and microglial markers.
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Fig. 1. Chronic intracerebroventricular (icv) infusions of the amylin receptor antagonist, AC253, improve behavioral performance and spatial memory in
TgCRND8 Alzheimer’s disease mouse model. (A) Schedule and timeline for behavioral testing and administration of icv AC253. (B1, C1) Data from Morris
Water Maze (MWM) testing shows daily escape latencies during platform trials of either wild-type (Wt) or TgCRND8 (Tg) mice receiving icv artificial cerebrospinal fluid (CSF) or AC253 at the age of 3 and 8 months (n 5 7 mice in each group; ***P ,.001 Tg-CSF vs. Tg-AC253). (B2, C2) Probe tests (for retention
of platform placement) show comparative analysis of time spent in the four quadrants between treatment groups of Wt and TgCRND8 mice. Target Q, quadrant
where the platform is located. (B3, C3) Graph showing the percentage of alteration in T-maze test. (n 5 7 mice in each group, *P , .05, **P , .01).

Peptides AC253, cAC253, and their fluorescent derivatives
were synthesized in situ and tested for their amylin receptor
antagonist properties using In-cell Western cyclic adenosine
monophosphate (cAMP) assay. Neuroprotective properties
of cAC253 were confirmed using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and live/dead
cell assays on cultures of HFNs and N2a cells. Flow cytom-

etry studies were performed to establish specificity of
cAC253 binding to the amylin receptor using HEK293 cells
expressing AMY3. In vivo and ex vivo imaging of brains was
carried out after single ip injection of fluorescently labeled
(Cy5) cAC253 to examine its pharmacokinetic profile, proteolytic stability, brain penetrability, and binding to amylin
receptors compared with linear AC253. To examine
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accumulation and specificity of binding for cAC253 to amylin receptors, brain imaging and histologic examination were
performed on three genetic strains of mice (TgCRND8, het
CTR, and Wt) expressing different levels of amylin receptors after a single ip injection of labeled cAC253.
2.3. Statistical analysis
The statistical data are presented as the mean 6 standard
error of the mean unless otherwise specified. Significance
was determined by one-way analysis of variance, followed
by Tukey’s post hoc test with Prism software (GraphPad
Prism 5; GraphPad Software, San Diego, CA). Differences
between groups were considered to be significant at P , .05.
Full detailed descriptions of methods are available in
Materials and Methods of the Supplementary Material.
3. Results
3.1. AC253 icv infusion improves cognitive deficits in a
transgenic animal model of AD
To determine whether amylin receptor antagonists can
prevent spatial memory and learning deficits, we performed
continuous icv infusions of AC253 or CSF in TgCRND8 or
Wt mice, starting at the age of 3 months for 5 months, and
measured behavior using MWM and T-maze tests before
and after the treatment. At the age of 3 months, no differences in spatial memory and learning were detected in either
the MWM or the T-maze between Wt and Tg mice
(Fig. 1B1–B3). However, at the age of 8 months, the
TgCRND8 mice receiving AC253 showed a marked
improvement in latencies to locate the hidden platform
over their Tg littermates receiving CSF; Wt control subjects
showed no memory deficits with either AC253 of CSF infusions (Fig. 1C1). TgCRND8 mice that were treated with
AC253 showed improved memory in probe trial for location
of the target quadrant (Fig. 1C2). For the T-maze test,
TgCRND8 mice that received AC253 showed an increased
percentage of correct arm (food rewarded) choice in Tmaze alternation task compared with CSF-treated
TgCRND8 mice (Fig. 1B3 and C3). These results indicate
that AC253 can prevent cognitive decline in aged APPexpressing mice. None of the mice receiving AC253 show
any signs of off-target effects (e.g., sedation, visible signs
of motor dysfunction, abnormal feeding or drinking
behavior and weight loss, changes in gross appearance
such as hair loss, and lack of grooming) throughout the
5 months of treatment, and no significant changes in body
weight were observed. These results indicate that AC253
can prevent cognitive decline in aged TgCRND8 mice.
Pathologic examination of mice brains showed no significant difference in the levels of soluble Ab1–42 or APP protein expression between the two Tg groups (CSF and
AC253) as measured by ELISA and Western blot, respectively (Supplementary Fig. 1A-C). There was a trend toward
a reduction in Ab plaque deposition after AC253 icv infu-
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sion; however, the difference was found to be statistically
nonsignificant (Supplementary Fig. 1D). AC253-treated Tg
group showed an increase of 40% and 30% in the expression
level of synaptic proteins, synapsin 1 (P , .01) and synaptophysin (P , .05), respectively, compared with Tg-CSF control subjects (Supplementary Fig. 1F). The expression levels
of Iba-1, a microglial marker, were significantly reduced (by
50%) in the Tg-AC253 group compared with the Tg-CSF
group (P , .05). This finding was further confirmed using
immunofluorescence staining (Supplementary Fig. 1F).
The amylin receptor (CTR and RAMP3 proteins) expression
levels in the brain showed no noticeable difference in
the levels of either protein between brains of the two
transgenic groups receiving either AC253 or CSF
(Supplementary Fig. 1E).
3.2. Cyclic AC253 blocks AMY3 receptor activation and
Ab neuronal cell death in vitro
Rapid metabolism by proteolytic enzymes and poor
pharmacokinetics are major drawbacks that limit the general use of linear peptides as therapeutic agents. Therefore,
on the basis of the promising in vivo efficacy of AC253
peptide on cognitive functions, we decided to develop a
new cyclized analog of AC253 (namely, cAC253) for
further testing. Peptide cyclization imposes structure rigidity, which enhances binding and selectivity toward the
target receptor (agonist/antagonist) and improves enzymatic stability [21,22]. Restriction of peptide backbone
flexibility would prevent liable amino acids from
orientating itself in the appropriate position for attack by
hydrolytic enzymes. Several cyclic peptides found in
nature are used in clinic. The examples are gramicidin
and tyrocidine with bactericidal activity, cyclosporin A
with immunosuppressive activity, and vancomycin with
antibacterial activity, and so on. Accordingly, we
imposed a conformational constraint on the cAC253
structure by placing two cysteine residues at both the C
and N termini and cyclized it through disulfide bond
formation as depicted in Fig. 2A. Synthetic peptides
AC253 and cAC253 were obtained in high yields, 40%
and 55%, respectively, and purity greater than 97% for
both peptides (Supplementary Table 1). Matrix assisted
laser desorption ionization-time of flight (MALDI-TOF)
mass spectrometry yielded molecular weights in good
agreement with the predicted masses of peptides, linear
AC253 showed m/z 2805.2 ([M 1 H]1 calculated
2085.4), and cAC253 m/z 3008.5 ([M 1 H]1 calculated
3008.8) (Supplementary Fig. 2). Partition coefficient
values of peptides proved that both are hydrophilic having
log P values of 21.2, and 21.05 for AC253 and cAC253,
respectively.
Next, we examined cyclization of the AC253 peptide for
its antagonist activity at AMY3 and whether it also retained
its neuroprotective properties against Ab toxicity using
two in vitro functional bioassays. Amylin receptors are

48

R. Soudy et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 44-56

Fig. 2. cAC253 retains its amylin receptor antagonist and neuroprotective properties against Ab1–42 cytotoxicity. (A) AC253 and cAC253 amino acid sequences
and structure. cAC253 has two additional cysteine amino acids at the C and N termini compared with AC253 and is cyclized using disulfide bond. (B) In-cell
Western assay showing both AC253 and cAC253 are capable of inhibiting human amylin (hAmylin) effects on the cellular levels of cyclic adenosine monophosphate (cAMP) via AMY3 receptor activation in HEK293 AMY3-expressing cells. Graph showing changes in cAMP levels in AMY3-expressing
HEK293 cells after exposure to different concentrations of AC253 and cAC253 peptides in the presence of 1 mM hAmylin. (C, D) Ab1–42 (10 mM) applied
to primary cultures of human fetal neurons (HFNs) or N2a neuronal cell line induces cell death (measured by MTT assay) that can be attenuated by preapplications of 10 mM either AC253 or cAC253 (n 5 5, *P , .05) (E) Photomicrographs of live (calcein-green fluorescence)/dead (ethidium-red fluorescence) assay
in HFNs, showing the effect of cAC253 or AC253 preincubation on the Ab1–42- and hAmylin-induced cell death. Scale bar 5 100 mm. (F) Histograms showing
quantification of live/dead assay. n 5 8, *P , .05; **P , .01. Abbreviation: Dapi, 4’,6-diamidino-2-phenylindole.

heterodimers of CTR and one of three RAMPs (RAMP1, 2,
and 3), thus generating multiple amylin receptor subtypes,
AMY1, AMY2, and AMY3 [23]. Our previous data provide
evidence that the AMY3 is the most relevant subtype of amylin receptors in the context of the direct actions of Ab (and
hAmylin) at the level of the cell membrane [10], and we
thus targeted this receptor isoform in the present study.

Both peptides of AC253 and cAC253 blocked the hAmylinevoked cAMP increase in a dose-dependent manner;
cAC253 was, however, threefold more potent in inhibiting
AMY3 receptor activity in AMY3 stable expression
HEK293 cells (AMY3-HEK) (Fig. 2B). The AC253 or
cAC253 alone had no effect on the cAMP level
(Supplementary Fig. 3A). The half-maximal inhibitory
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Fig. 3. cAC253 has enhanced specific binding to AMY3 receptor invitro compared with linear AC253. (A) Flow cytometry histograms comparing Cy5-labeled AC253
and cAC253 peptides (5 mM) for HEK293 AMY3 cells binding and uptake after 60 minutes of incubation in serum-free media at 37 C. (B, C) Graphs showing the
dose-dependent uptake of Cy5-labeled peptides in HEK293 AMY3 cells and quantification of cell uptake of peptides at 4 C in the presence of cytocholasin D (CytoD,
an endocytosis inhibitor) and in the presence of human amylin (a competitive binding inhibitor). Data are from two independent experiments carried out in triplicate
(n 5 8 for each point, *P , .05; **P , .01). (D) Representative fluorescence microscopy images showing Cy5-labeled peptides binding to GFP-labeled HEK293
AMY3 cells at 37 C for 60 minutes of incubation (scale bar 5 10 mm). Abbreviations: DAPI, 4’,6-diamidino-2-phenylindole; GFP, green fluorescent protein.

concentration for AC253 and cAC253 was approximately
0.85 and 0.3 mM, respectively.
Soluble oligomeric Ab is known to be toxic in neuronal
cell cultures, and we previously demonstrated that AC253
attenuates Ab1–42- and hAmylin-induced apoptotic cell
death in cultured human neurons via its antagonist activity
at the AMY3 receptor [13]. Therefore, we examined whether
in vitro cAC253 can protect neuronal cells, HFNs and N2a,
from Ab1–42-induced cytotoxicity. Using the MTT and live/
dead assays, we observed that both peptides were equally
effective in attenuating cell death induced by Ab1–42 and hAmylin (Fig. 2C–F). Thus, our results confirmed that cAC253
retained its amylin receptor antagonist and neuroprotective
properties against Ab toxicity.
3.3. cAC253 has enhanced binding to AMY3 receptor
in vitro
We next examined the in vitro binding efficacy and specificity of cAC253 compared with AC253 in AMY3-HEK cells
using flow cytometry and fluorescence microscopy. Cy5 nearinfrared (NIR)-fluorescently labeled peptides (AC253 and
cAC253) were synthesized and characterized using

MALDI-TOF mass spectrometry, which displayed molecular
weights in agreement with calculated values (Supplementary
Table 1). From flow cytometry assay (Fig. 3A), cAC253 displayed threefold enhanced binding and uptake into AMY3HEK cells compared with AC253 with mean fluorescence intensity of 3300 and 1200 for cAC253 and AC253, respectively.
This enhanced binding explains the observed improvement in
the antagonistic activity of cAC253 at the amylin receptors using a cAMP assay in AMY-expressing HEK293 cells. Cell
binding to both antagonists increases in a dose-dependent
manner with Kd of 1.45 6 0.5 and 2.6 6 1.0 mM for
cAC253 and AC253, respectively (Fig. 3B). Further increase
in peptide concentration beyond 10 mM revealed saturation,
suggesting that these peptides bind and interact with the
AMY3-HEK cells through a receptor-based mechanism. In
Wt HEK293 cells, both antagonists demonstrated a 10-fold
decrease in binding and uptake compared with that for
AMY3-HEK cells, thus further confirming AMY3 binding
specificity (Supplementary Fig. 3B). To determine the intracellular delivery mechanisms, we examined the delivery efficiency of our peptides at different temperatures, 4 C and
37 C, and in the presence of cytochalasin D (CytoD), an inhibitor of endocytosis via clathrin-coated pits. Both peptides
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behaved similarly and a marked decrease in binding and uptake was observed at 4 C with mean fluorescence intensity
of 356.6 6 35 and 400 6 75 for cAC253 and AC253, respectively, indicating that peptide cell uptake occurs via an energydependent endocytic pathway (Fig. 3C). In the presence of CytoD, the cell uptake of both peptides was significantly
decreased (threefold) with mean fluorescence intensity of
1100 6 100 and 450 6 50, for cAC253 and AC253, respectively, suggesting that clathrin endocytosis is, at least in part,
responsible for the uptake of peptides (Fig. 3C). Binding of
the antagonists to AMY3-HEK cells was competitively inhibited when cells were preincubated with unlabeled hAmylin, and peptide cell uptake was partly inhibited with mean
fluorescence intensity of 1250 6 200 and 500 6 100 for
cAC253 and AC253, respectively (Fig. 3C). With fluorescence microscopy, we observed strong binding of both peptides to the cell membrane of AMY3-HEK cells (Fig. 3D).
3.4. cAC253 has better brain penetration,
pharmacokinetic profile, and enzymatic stability than
AC253
For peptidergic drugs to be an effective therapy for AD,
they must achieve an effective concentration in the CNS

after peripheral administration. Therefore, using the fluorescently labeled peptides, we examined and compared the ability of cAC253 and AC253 to penetrate the blood–brain
barrier (BBB) in Wt mice using NIR fluorescence in vivo,
and ex vivo brain imaging. After single ip administration,
the fluorescence signal for both peptides was significantly
increased in the brain, and it was detectable in brain regions
within 10 minutes after injection. Interestingly, cAC253
showed a stronger brain fluorescence signal compared with
AC253 at all-time points. The fluorescence signal for
cAC253 was slowly washed out, even it was clearly visible
at 24 hours time point, indicating its higher brain retention
(Fig. 4A). A peak fluorescence signal for both peptides was
observed at 2 hours, which was therefore selected as an
optimal time point for further ex vivo experiments. To ensure
that the fluorescence observed was mainly because of the
peptide, Cy5 dye was injected alone and brain imaging
showed that it could not on its own cross the BBB. Furthermore, to confirm if cAC253 peptide is indeed in its
intact form in the brain, we used liquid chromatography
tandem-mass spectrometry (LC-MS/MS) on brain tissue
homogenates that received the ip injection. As shown in
reversed-phase high-performance liquid chromatography

Fig. 4. cAC253 demonstrates superior brain permeability, pharmacokinetic profile, and proteolytic stability compared with AC253. (A) In vivo near infrared
fluorescence (NIRF) brain imaging of Cy5 AC253 and cAC253 peptides compared with saline injections administered intraperitoneally in wild-type (Wt) mice
at 0, 2, 24 hours of time points using Kodak imager. (B) Ex vivo images of brains from Wt mice receiving intraperitoneal (ip) injections of 0.1 mmol AC253 or
cAC253 in 200 mL saline compared with saline-injected mice (control). (C) Quantification of brain fluorescence intensity after 2 hours of ip injection of labeled
peptides (n 5 5 in each group, *P ,.05, **P , .01). (D) Brain sections from ex vivo experiments in (B) showing AC253 and cAC253 fluorescent labeling (red)
within the hippocampus and nuclear staining with 4’,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar 5 100 mm. (E) Ex vivo fluorescence brain images
showing time-dependent accumulation of cAC253 after a single ip injection of 0.1 mmol of the peptide in 200 mL saline. (F) Quantification of the data shown in
(E) for brain accumulation of labeled cAC253 at different time points (n 5 3). (G) In vitro stability of cAC253 peptide in human serum compared with AC253 at
37 C. The amount of intact peptide in human serum at different time points was estimated using RP-HPLC.
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(RP-HPLC) chromatograms, consistent with Cy5-cAC253
control peak that elutes at 37 minutes, a similar peak was
identified in the brain homogenate from animals that received
cAC253. Mass spectrometry of the eluted peak at the denoted
retention time revealed a molecular weight of 730.156
([M 1 5H]1 calculated 730.512), consistent with that of
the full length peptide and supporting the conclusion that
the cAC253 reaches the brain intact (Supplementary Fig. 4).
Next, we compared the brain concentrations of cAC253
peptide to that of a well-studied peptide, T7 peptide
(HAIYPRH). T7 uses the transferrin receptor to penetrate
the BBB and achieve therapeutic concentrations in the brain
[24,25]. Ex vivo brain fluorescence signal from cAC253 was
comparable to the fluorescence of the T7 peptide-injected
group after 2 hours of injection, (Supplementary Fig. 5).
The brain cAC253 concentration after injecting 40 mg Cy5cAC253 was estimated to be in the range of 10 to 100 nM,
a level equal to 0.1% of the injected dose (Supplementary
Fig. 6). These estimates of brain levels are comparable to
the reported values for various well-studied bioactive peptide
hormones such as amylin or insulin [26,27].
Ex vivo brain imaging 2 hours after ip injection was
consistent with the in vivo imaging data, and the signals
from peptides injected into mice brains were 2.8- and 2fold higher for cAC253 and AC253, respectively, than saline
injection. In addition, the signal from cAC253 was 1.4-fold
higher than AC253 (Fig. 4B and C). Interestingly, although
the peptides were distributed throughout the entire brain,
the fluorescence was strongly localized to the hippocampal
region, which also coincides with the localization of amylin
receptor expression in the brain [28]. Histologic analysis of
ex vivo–imaged brains confirmed that our peptides were
mainly accumulated in the hippocampal region (Fig. 4D).
To further investigate the role of amylin receptor in peptide
brain uptake, an in vivo competition experiment was performed where mice were injected with Cy5-cAC253 along
with a fivefold excess of unlabeled cAC253 peptide. The
brain fluorescence signal in animals receiving the peptides
mixture was significantly reduced (by w75%) in comparison to the Cy5-cAC253 only (Supplementary Fig. 7). Overall our results demonstrate, for the first time, the ability of
amylin receptor antagonist peptides (cAC253 and AC253)
to penetrate the blood-brain barrier when given peripherally
and support the notion that the brain uptake of these peptides
occurs via an amylin receptor-based mechanism.
Next, we examined the pharmacokinetic profile and the
proteolytic stability of cAC253 in vivo and in vitro, respectively. We assessed the time dependence for peptide cAC253
to clear from the Wt mouse brain after injecting 20 mg/kg
intraperitoneally (Fig. 4E and F). Cy5-cAC253 fluorescence
signal in the brain reached its maximum at 6 hours after
which it slowly declined with an estimated half-life in brain
of 16 hours. We next analyzed brain fluorescence levels in
mice 2 hours after receiving 0.2, 2, or 20 mg/kg of
cAC253 as a single ip dose. Cy5-cAC253 brain fluorescence
appears to be concentration-dependent and saturable
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because a dose increment from 2 to 20 mg/kg achieved a
steady state level, which suggests a receptor-mediated brain
uptake of this peptide (Supplementary Fig. 8).
Biodistribution evaluation cAC253 in different organs
(liver, kidney, spleen, lung, heart, brain, stomach, and intestine) was investigated 2 hours after injecting 20 mg/kg peptide. Ex vivo fluorescence signals indicated that peptide was
distributed within all organs examined although uptake in
lung, spleen, and heart was considerably less compared
with the kidney and the liver, which showed a strong NIR
fluorescence intensity in keeping with renal and hepatic
clearance of the peptide. AC253 biodistribution data show
similar pattern to the cAC253 with observed less accumulation in the brain (Supplementary Fig. 8). Also, we did not
observe any histopathologic changes in the kidney or liver
from icv AC253-treated mice.
Next, we investigated the influence of cyclization on the
proteolytic stability of cAC253 compared with AC253.
cAC253 was found to be seven times more stable in human
serum compared with AC253 with 7- and 1-hour half-lives,
respectively. This confirms that cyclization of AC253
enhanced its stability and conferred protection from proteolytic cleavage, thus increasing the amount of peptide reaching the brain through the systemic circulation (Fig. 4G). By
assessing the main degradation fragments in both peptides
with MALDI-TOF, both peptides were found to be cleaved
at the basic arginine amino acids R3, R10, and R16. Overall,
cAC253 is an excellent candidate for peripheral administration and behavioral testing.
3.5. cAC253 targets the AMY receptor in vivo
To study the connection between the expression level of
the amylin receptor and the degree of cAC253 brain permeability, peptide brain fluorescence signal was compared in
two genetically engineered mouse models that express
differing levels of the CTR receptor. We used two engineered mouse resources: hemizygous CTR mice that exhibit
50% CTR expression (“het CTR”) and hence 50% reduction
in the functional amylin receptor [20] and transgenic APPoverexpressing (TgCRND8) mice known to have upregulation of the amylin receptor [13]. After 2 hours of ip injection,
ex vivo brain imaging results demonstrated that the fluorescence of cAC253 in brains of TgCRND8 mice increased by
45% compared with Wt age-matched control subjects
(Fig. 5A and B). However, for het CTR mice, the brain fluorescence decreased by 30% compared with that of Wt mice
(Fig. 5A and B). These data therefore indicate that the
amount of cAC253 uptake and accumulation positively correlates with the level of amylin receptor expression in the
brain. These observations were further confirmed by immunohistochemical examination of brain sections, which
showed that the amount of cAC253-labeled peptide within
the hippocampus is correlated to the level of CTR expression
(Fig. 5C). In addition, CTR is colocalized with the labeled
cAC253. Examination of histologic sections also revealed
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Fig. 5. Cyclic AC253 brain uptake correlates with the expression of amylin receptor levels in the brain (A) Brain images from wild-type (Wt), heterozygous
CTR knockdown (het CTR, 50% depletion of amylin receptors), or TgCRND8 (that overexpress amylin receptors) mice 2 hours after receiving equimolar intraperitoneal (ip) injections of Cy5-cAC253 (0.1 mmol in 200 mL saline). (B) Quantification of data for brain accumulation of Cy5-cAC253 in the three distinct
mouse genotypes. (n 5 5 in each group, *P , .05, **P , .01). (C) Brain sections from the three mouse genotypes showing fluorescent labeling through the
hippocampus after a single ip injection of Cy5-labeled cAC253 (scale bar 5 100 mm). Abbreviation: DAPI, 4’,6-diamidino-2-phenylindole.

intense CTR staining along the endothelial cells of the cerebral vessels supporting the notion that the amylin receptors
most likely play a role in the brain uptake of the peptide
from the vasculature, a hypothesis that is currently under
investigation (Supplementary Fig. 9).
3.6. Peripheral administration of cAC253 improves
cognitive deficits in transgenic mouse model of AD
On the basis of the superior stability, pharmacokinetic
profile, and brain penetrability of cAC253 compared with
linear AC253, we sought to determine the benefits of
cAC253 on spatial memory in TgCRND8 mice when administered systemically. Starting at the age of 3.5 months,
groups of TgCRND8 or Wt mice (n 5 10 for each group)
received either cAC253 (200 mg/kg) or NS intraperitoneally
three times a week for 10 weeks. The dose of cAC253 for ip
injection was based on the calculated steady state dose of

AC253 from the icv experiments, and its frequency of
administration was based on the estimated half-life of
cAC253 in the brain and serum from our in vivo experiments.
Results showed that at the age of 3 months, no differences
in spatial memory and learning deficits were detected in the
MWM between Wt and Tg mice (Fig. 6A). However, after
10 weeks of cAC253 ip injections, TgCRND8 mice showed
a marked improvement in the MWM test of spatial memory
compared with Tg littermates receiving saline. Wt control
subjects showed no alterations in spatial memory with either
cAC253 or saline injections (Fig. 6A). TgCRND8 mice
treated with cAC253 also showed an improved ability to
retain location of the platform in the target quadrant after
24 hours (Fig. 6B). TgCRND8 and Wt mice receiving
cAC253 did not demonstrate any off-target effects such as
sedation, weight loss, signs of abnormal motor dysfunction,
feeding/drinking behavior, and hair loss. These animals also
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did not demonstrate any weight loss over the course of the
entire experiment.
After 10 weeks of cAC253 ip injection, Ab plaque
formation was significantly reduced in both the number of
Ab plaques and total area of Ab-positive profiles in the
cAC253-treated Tg group compared with Tg saline injected
mice (Fig. 6C and D).
4. Discussion
The present study shows, for the first time, that chronic
central administration of the amylin receptor antagonist,
AC253, results in an improvement of the age-dependent
spatial memory and learning deficits in transgenic APPoverexpressing (TgCRND8) mice. TgCRND8 mice carry
combined APP Swedish (K670M/N671L) and Indiana
(V717F) mutations, resulting in an aggressive neuropathology evident by 6 months when the animals also demonstrate large numbers of diffuse and plaque amyloid deposits
[29,30]. These mice exhibit normal behavior at the age of 3
to 4 months, but by 6 months they show a progressive
deterioration of cognitive function and spatial memory
with increased Ab burden. In tests of memory retrieval
(MWM, T-maze, and probe trial for quadrant preference),
8 month-old TgCRND8 mice, which had received icv infusions of AC253 for more than a period of 5 months, demonstrated a superior performance to age-matched TgCRND8
mice that received CSF infusions. In spite of the duration
of drug infusions, we did not observe any off-target effects
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and mortality within the groups of TgCRND8 mice
receiving either CSF or AC253 was identical at 20%, a figure
consistent with that reported by other groups that have used
this genetic strain of mice [29,30]. The long-term central
administration of amylin receptor antagonist, AC253, therefore appears to be a viable, relatively safe disease-modifying
treatment in an AD mouse model.
We have previously shown using several in vitro experimental paradigms that the deleterious effects of Ab are expressed via its direct actions on amylin receptors and these
effects can be blocked with AC253 [13,15]. In addition,
both AC253 and pramlintide restore the Ab- and hAmylinevoked depression of hippocampal LTP, a cellular surrogate
of memory [16,19]. We surmised the same mechanism, that
is, blocking the brain amylin receptors could account for
the in vivo improvement in spatial memory and learning
observed in AC253-treated TgCRND8 AD mice. We also
examined the brains of Wt and TgCRND8 mice receiving
CSF or AC253 to determine whether the antagonism of amylin receptors with AC253 affected markers of AD pathology.
Our data revealed that although icv AC253 did not have a statistically significant effect on the total brain levels of APP, Ab
in plaque form, or soluble oligomers of Ab, there appeared to
be a trend toward reduction of the amyloid burden. With systemic administration of cAC253, we did, however, observe a
significant reduction in amyloid plaque size and area in
treated mice versus control subjects. This would be consistent with prior observations that systemic injections of amylin and pramlintide reduce brain amyloid in transgenic AD

Fig. 6. Peripheral administration of cAC253 improves cognitive function in transgenic AD mice. (A, B) Younger (3 month-old, 3 m) transgenic (Tg) AD mice
(TgCRND8) show no significant cognitive impairment compared with their wild-type (Wt) littermates as measured by escape latencies in the Morris Water
Maze (MWM) (A) and quadrant preference on probe test (B). At the age of 6 months, TgCRND8 mice began to show cognitive impairment compared with
Wt control subjects, whereas intraperitoneal administration of the amylin receptor antagonist, cAC253 (cAC, three times a week for 10 weeks commencing
at the age of 3 months) significantly improves MWM and quadrant preference performance compared with Tg mice receiving normal saline (NS). In (A),
S1, S2, and S3 refer to the number of the trial session for MWM. (C, D) Immunohistochemical detection of amyloid plaques in brains of saline (NS) or
cAC253 (cAC)-treated TgCRND8 mice reveals a significant reduction of the amyloid plaque burden in mice receiving cAC253. *P , .05, **P , .01. Scale
bar 5 200 mm.
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mice [27]. Thus, amylin analogs and antagonists both appear
to be capable of reducing brain concentrations of amyloid,
thereby providing another beneficial mechanism for
amylin-based therapies in AD. No differences in the levels
of amylin receptor (CTR or RAMP3) expression were
observed in Wt or TgCRND8 mice with either CSF or
AC253 administration. On the other hand, we did observe a
significant increase in synaptic markers (synapsin 1 and synaptophysin) in TgCRND8 mice that received AC253
compared with those receiving CSF. Interestingly, there
was also a significant suppression of the microglial marker,
Iba1, in the brains of AC253-treated TgCRND8 mice.
AC253 may thus improve not only synaptic function as has
been observed for in vitro studies of LTP [16,19] but also
attenuate disruption of synaptic integrity in TgCRND8
mice that is attributed to increased Ab burden. Amylin
receptors have also been reported on human microglia and
deemed to participate in Ab-induced activation of
inflammasome and cytokine release [31]. Thus, attenuation
of this Ab-driven inflammatory cascade by blockade of amylin receptors with AC253 could in part explain the decreased
microglial activation in brains of TgCRND8 mice.
Peptide-based drugs have limited therapeutic utility for
CNS disorders chiefly on account of their limited BBB
permeability with the failure of beta-secretase 1 (BACE1)
inhibitors being a case in point [32]. AC253 is a 24-amino
acid peptide whose sequence is extremely hydrophilic in nature, and thus we initially assessed its effects on spatial
memory in vivo through an icv route of administration that
would deliver the drug directly to the brain. Chronic icv
administration of AC253 although beneficial, however, is
not practical. We therefore developed a cyclized version of
the AC253 peptide (cAC253) through disulfide linkage to
improve its physiochemical and biological activity and brain
penetrability compared with its linear counterpart. Our
design was based on several key factors. First, gaining a
fixed geometry through cyclization would enhance
peptide-specific and efficient binding to the amylin receptor.
Second, because amylin receptors exist as several subtypes
(AMY1, AMY2, and AMY3), we hoped that the fixed geometry of cAC253 in comparison to AC253 would also make it
more selective for particular receptor subtypes (AMY1 and
AMY3) that are more prevalent in the brain [33,34]. In
addition, cyclization also enhances peptide enzymatic
stability [35]. We achieved these goals by demonstrating
that cyclization in fact enhanced AC253 binding to
AMY3-expressing cells and resulted in superior bloodbrain barrier permeability after a single ip injection
compared with a linear form of AC253 at therapeutically
relevant concentrations. Furthermore, cAC253 showed a
sevenfold increase in proteolytic stability (t1/2), and better
pharmacokinetic profile compared with AC253. In comparison to commercially available pramlintide (Symlin, AstraZeneca), cAC253 offers multiple advantages over
pramlintide in the form of better solubility at physiological
pH [36], superior brain penetrability when administered sys-

temically (Supplementary Fig. 10), and a shorter peptide
sequence that renders it more cost effective therapeutic
agent. cAC253 also has a longer duration of action and
thus higher bioavailability, which was evident by a lower
number of injections per week (three) than required for
pramlintide (daily) [18].
Systemic administration of cAC253 for 10 weeks in a
mouse AD model recapitulated the improvement in spatial
memory evoked by chronic icv infusions of the linear form
of the peptide, AC253. TgCRND8 mice receiving cAC253
demonstrated improved escape latencies on MWM testing
and also an ability to retain the location of the target quadrant (for the platform). Similar to icv AC253, we did not
observe any morbidity or off-target effects of cAC253
administration. The behavioral improvement was also
accompanied by a reduction of the amyloid plaque burden
in TgCRND8 mice receiving cAC253 compared with saline
control subjects. Our data thus identify cAC253 as a novel
and potent CNS-permeable peptide that holds promise as a
potential therapy for AD. Furthermore, on account of its
brain permeability, cAC253 could be used even for wider applications such as serving as a carrier to facilitate delivery of
a variety of therapeutic or imaging molecules into the brain.
An important observation in the present study relates to
the positive correlation between cAC253 uptake across the
blood-brain barrier and the expression levels of the amylin
receptor in the brain. In hemizygous CTR mice, which
exhibit a 50% knocked down of the CTR (and hence amylin)
receptor, we observed a significantly reduced cAC253 fluorescent labeling in the brain including the hippocampus
compared with Wt mice that carry a normal complement
of amylin receptors. On the contrary, for TgCRND8 mice,
in which we have previously reported an upregulation of
the amylin receptors [13], cAC253 fluorescence was markedly increased in the same brain regions. Binding of
cAC253 to amylin receptors is also supported by the finding
that injection of a mixture of Cy5 fluorescently labeled
cAC253 and free unlabeled cA253 peptide resulted in a
75% reduction in brain fluorescence levels in comparison
to animals injected with the fluorescently labeled cAC253
only. We also observed intense histologic staining for CTR
along the endothelial cells of the cerebral vessels in
TgCRND8 and Wt mice supporting the possibility that the
amylin receptors may be involved in the brain uptake of
the amylin peptide from the vasculature. This notion is supported by studies in the cat, where amylin immunoreactive
fibers were shown to innervate cerebral vessels and application of this peptide resulted in a relaxation of ring segments
of the middle cerebral artery containing endothelium [37].
5. Conclusions
The present study demonstrates that chronic treatment
with amylin receptor antagonists improves spatial memory
in transgenic model of AD mice, and histopathologic examination shows an increase in markers of synaptic integrity
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and a reduction in microglial activation. Cyclized form of
the amylin receptor antagonist, AC253, demonstrates superior proteolytic stability and brain penetration than the linear
form of this peptide and its presence in the brain correlates
with the levels of expression of the amylin receptor. Collectively, these observations validate the amylin receptor as a
therapeutic target and development of amylin receptor antagonists could serve as effective disease-modifying therapy
in AD progression.
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RESEARCH IN CONTEXT

1. Systematic review: At present there are no Food and
Drug Administration–approved disease-modifying
therapies for Alzheimer’s disease. On the basis of
our work and that of others, we tested whether
administration of the amylin receptor antagonist,
AC253, in an Alzheimer’s disease (AD) mouse
model of mice improves spatial memory and
learning.
2. Interpretation: We show that chronic central administration of AC253 improves spatial memory in transgenic AD mice and is well tolerated. We further have
developed a cyclized form of AC253 (cAC253) that
when administered systemically is proteolytically
stable, readily brain penetrant, and binds to hippocampal amylin receptors while retaining its neuroprotectant properties and its ability to improve
spatial memory and learning in TgCRND8 mice.
3. Future directions: Amylin antagonists could serve as
novel therapeutic compounds for AD. We plan to
identify peptide fragment sequences of AC253 that
retain the beneficial effects of parent compound
AC253 but offer advantages in terms of their synthesis, stability, and administration.
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